Lung cancer is the leading cause of cancer death in the world, with non-small cell lung cancer (NSCLC) a significant component of those deaths.1,2 Treatments for advanced-stage NSCLC, however, are limited. Erlotinib, a small-molecule tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), has aided in advancing NSCLC therapy. Erlotinib has been shown to increase survival by 2 months compared with placebo in a phase 3, randomized controlled trial when used as second- or third-line therapy.3 The authors present a case of a man surviving almost 8 years with late-stage NSCLC on treatment with erlotinib at the VA West Los Angeles Medical Center (WLAMC).
Clinical Topics & News
Long-Term Survival of a Patient With Late-Stage Non-Small Cell Lung Cancer
After not responding to chemotherapy and monoclonal antibody therapy, a patient with late-stage non-small cell lung cancer benefited from treatment with erlotinib.
Clinical Topics
-
Despite benefits, extended-interval pembro uptake remains low -
Time to cancer diagnoses in U.S. averages 5 months -
Opioids after lung cancer surgery may up all-cause mortality risk -
Gene mutations may drive lung cancer in never-smokers -
Reporting Coronary Artery Calcium on Low-Dose Computed Tomography Impacts Statin Management in a Lung Cancer Screening Population
Digital Edition
Multimedia
Conference Coverage
-
Neoadjuvant, adjuvant, or both? The debate in NSCLC rages on -
‘We finally made it’: Amivantamab comes of age in NSCLC -
ALK inhibitor alectinib shows DFS benefit in early NSCLC -
Perioperative nivolumab improves EFS in resectable NSCLC -
Higher RT doses can boost lifespan, reduce risk of death in LS-SCLC patients -
Reducing cognitive impairment from SCLC brain metastases -
Therapeutic vaccine shows promise in treating lung cancer -
Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC -
Proposed TNM update could shift staging for lung cancers -
Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study
Question 1 of 5
